Hostname: page-component-7bb8b95d7b-l4ctd Total loading time: 0 Render date: 2024-09-23T04:50:16.622Z Has data issue: false hasContentIssue false
  • English
  • Français

Vagus Nerve Stimulation Therapy in a Patient with Treatment-Resistant Depression: A Case Report of Long-Term Follow-up and Battery End-of-Service

Published online by Cambridge University Press:  07 November 2014

James M. Martinez  and
Holly A. Zboyan
Get access Rights & Permissions [Opens in a new window]

Abstract

This is the first case report of a patient who received long-term (69-month) adjunctive vagus nerve stimulation (VNS) therapy for treatment-resistant depression (TRD) and reached VNS battery end-of-service (EOS).The patient is a 41-year-old female with depression who entered a study of adjunctive VNS therapy for TRD. Her Hamilton Rating Scale for Depression (HAM-D) scores dropped from a mean of 33.5 (pre-implantation baseline period) to 16 at the end of the 12-week acute-phase treatment period, and then fluctuated from <7 (normal range) to scores in the moderately depressed range (∼20) during long-term follow-up. Three and one-half years after VNS implantation, the patient's HAM-D scores began to increase from a score of 18 to a peak score of 27 ∼ 16 months later (5-years post-implantation). The patient subsequently reported that she could no longer feel stimulation from the device and device interrogation 2 weeks later indicated battery EOS. The patient was hospitalized due to worsened depression, the pulse generator was replaced, and medication adjusted. HAM-D scores through the subsequent 9 months of followup returned to a pattern of fluctuations within the range noted during the long-term follow-up period prior to VNS battery EOS.

Type
Case Report
Information
CNS Spectrums , Volume 11 , Issue 2 , February 2006 , pp. 143 - 148
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Ben-Menachem, E, Manon-Espaillat, R, et al.Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia. 1994;35:616–626.Google Scholar
2.Handforth, A, DeGiorgio, CM, Schachter, SC, et al.Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51:48–S5.Google Scholar
3.Morris, GL, Mueller, WM, Vagus Nerve Stimulation Study Group (E01-E05). Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology. 1999;53:1731–1735.CrossRefGoogle Scholar
4.Harden, CL, Pulver, MC, Ravdin, LD, Nokolov, B, Halper, JP, Labar, DR. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav. 2000;1:93–99.Google Scholar
5.George, MS, Sackeim, HA, Rush, AJ, et al.Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry. 2000;47:287–295.Google Scholar
6.Henry, TR, Bakay, RA, Votaw, JR, et al.Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: acute effects at high and low levels of stimulation. Epilepsia. 1998;39:983–990.Google Scholar
7.Ben-Menachem, E, Hamberger, A, Hedner, T, et al.Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res. 1995;20:221–227.CrossRefGoogle ScholarPubMed
8.Krahl, SE, Clark, KB, Smith, DC, Browning, RA. Locus coeruleus lesions suppress the seizure attenuating effects of vagus nerve stimulation. Epilepsia. 1998;39:709–714.CrossRefGoogle ScholarPubMed
9.Walker, BR, Easton, A, Gale, K. Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius. Epilepsia. 1999;40:1051–1057.Google Scholar
10.Sackeim, HA, Rush, AJ, George, MS, et al.Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–728.Google Scholar
11.Marangell, LB, Rush, AJ, George, MS, et al.Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280–287.CrossRefGoogle ScholarPubMed
12.Rush, AJ, Marangell, LB, Sackeim, HA, et al.Vagus nerve stimulation (VNS) for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347–354.Google Scholar
13.Rush, AJ, Sackeim, HA, Marangell, LB, et al.Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–363.Google Scholar
14.George, MS, Rush, AJ, Marangell, LB, et al.A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364–373.Google Scholar
15.Tatum, WO 4th, Ferreira, JA, Benbadis, SR, et al.Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service. Epilepsy Behav. 2004;5:128–132.Google Scholar
16.Vonck, K, Dedeurwaerdere, S, De Groote, L, et al.Generator replacement in epilepsy patients treated with vagus nerve stimulation. Seizure. 2005;14:89–99.Google Scholar